Detalles de la búsqueda
1.
Effectiveness and safety of 12-month certolizumab pegol treatment for axial spondyloarthritis in real-world clinical practice in Europe.
Rheumatology (Oxford)
; 60(1): 113-124, 2021 01 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32584415
2.
Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension.
Ann Rheum Dis
; 73(12): 2094-100, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-23918037
3.
Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX.
Rheumatology (Oxford)
; 51(7): 1226-34, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22344576
4.
A multicenter, open-label study to evaluate the safe and effective use of a new electromechanical auto-injection device for self-injection of certolizumab pegol.
Expert Opin Drug Deliv
; 17(6): 855-862, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32239971
5.
The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW.
RMD Open
; 6(1)2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32371433
6.
Comparative usability study for a certolizumab pegol autoinjection device in patients with rheumatoid arthritis.
Expert Opin Drug Deliv
; 14(1): 15-22, 2017 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-27801596
7.
A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis.
Arthritis Rheumatol
; 69(10): 1937-1948, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28666080
Resultados
1 -
7
de 7
1
Próxima >
>>